Literature DB >> 12834338

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Michael J Volles1, Peter T Lansbury.   

Abstract

Parkinson's disease (PD) is linked to mutations in the protein alpha-synuclein, which can exist in vitro in several aggregation states, including a natively unfolded monomer, a beta-sheet rich oligomer, or protofibril, and a stable amyloid fibril. This work reviews the current literature that is relevant to two linked questions: which of these species is pathogenic, and what is the mechanism of neurotoxicity? The amyloid fibril, fibrillar aggregates, Lewy bodies, and the alpha-synuclein monomer, which is normally expressed at high levels, are all unlikely to be pathogenic, for reasons discussed here. We therefore favor a toxic protofibril scenario, and propose that the pathogenic species is transiently populated during the process of fibrillization. Toxicity may arise from pore-like protofibrils that cause membrane permeabilization. An approach to testing this hypothesis is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834338     DOI: 10.1021/bi030086j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  123 in total

1.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 2.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

Review 3.  Nanopore analysis: An emerging technique for studying the folding and misfolding of proteins.

Authors:  Claudia Madampage; Omid Tavassoly; Chris Christensen; Meena Kumari; Jeremy S Lee
Journal:  Prion       Date:  2012-04-01       Impact factor: 3.931

Review 4.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 5.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

6.  Translocation of alpha-synuclein expressed in Escherichia coli.

Authors:  Guoping Ren; Xi Wang; Shufeng Hao; Hongyu Hu; Chih-Chen Wang
Journal:  J Bacteriol       Date:  2007-02-02       Impact factor: 3.490

7.  Calcitonin forms oligomeric pore-like structures in lipid membranes.

Authors:  Marco Diociaiuti; Laura Zanetti Polzi; Luisa Valvo; Fiorella Malchiodi-Albedi; Cecilia Bombelli; Maria Cristina Gaudiano
Journal:  Biophys J       Date:  2006-09-15       Impact factor: 4.033

Review 8.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

9.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

10.  DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Authors:  Sara Batelli; Diego Albani; Raffaela Rametta; Letizia Polito; Francesca Prato; Marzia Pesaresi; Alessandro Negro; Gianluigi Forloni
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.